Masatoshi Hanada1,2, Noriho Sakamoto3, Yuji Ishimatsu4, Tomoyuki Kakugawa3, Yasushi Obase3, Ryo Kozu4, Hideaki Senjyu4, Koichi Izumikawa2, Hiroshi Mukae3,5, Shigeru Kohno3. 1. Cardiorespiratory Division, Department of Rehabilitation Medicine, Nagasaki University Hospital, Nagasaki, Japan. 2. Department of Infectious Diseases Unit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 3. Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan. 4. Department of Cardiopulmonary Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 5. Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Abstract
BACKGROUND AND OBJECTIVE: Corticosteroids are occasionally used in the treatment of ILD. Chronic corticosteroid administration induces skeletal muscle weakness. However, it is unclear whether chronic corticosteroid treatment could further reduce skeletal muscle strength in patients with ILD who are weaker than healthy controls. The aim of this study was to determine the effects of chronic corticosteroid administration on skeletal muscle strength, exercise capacity, activities of daily living (ADL) and health status in ILD patients. METHODS: Forty-seven ILD patients treated with corticosteroids and 51 Medical Research Council dyspnea grade-matched ILD patients not treated with corticosteroids were assessed by isometric quadriceps muscle force (QF) and handgrip force (HF), pulmonary function, 6-min walk distance, ADL score and health status (Medical Outcomes Study 36-Item Short-Form Health Survey), and the two groups' results were compared. RESULTS: QF and HF were significantly lower in subjects on corticosteroids than in the control patients (QF, 52.6 ± 25.6 vs 77.1 ± 33.3 %predicted, P < 0.001; HF, 63.8 ± 22.4 vs 81.8 ± 28.3 %predicted, P < 0.001, respectively). There were no significant differences in the 6MWD, ADL score and all subscales of the SF-36 between the groups. Inverse correlations were found between skeletal muscle strength and total amount of corticosteroids administered (QF, r = -0.401, P = 0.005; HF, r = -0.403, P = 0.005). On multiple regression analysis, the total amount of corticosteroids was an independent predictor of HF. CONCLUSION: Chronic cor3ticosteroid treatment contributes to muscle weakness in ILD patients, and muscle weakness is inversely correlated to the total amount of corticosteroids administered.
BACKGROUND AND OBJECTIVE: Corticosteroids are occasionally used in the treatment of ILD. Chronic corticosteroid administration induces skeletal muscle weakness. However, it is unclear whether chronic corticosteroid treatment could further reduce skeletal muscle strength in patients with ILD who are weaker than healthy controls. The aim of this study was to determine the effects of chronic corticosteroid administration on skeletal muscle strength, exercise capacity, activities of daily living (ADL) and health status in ILDpatients. METHODS: Forty-seven ILDpatients treated with corticosteroids and 51 Medical Research Council dyspnea grade-matched ILDpatients not treated with corticosteroids were assessed by isometric quadriceps muscle force (QF) and handgrip force (HF), pulmonary function, 6-min walk distance, ADL score and health status (Medical Outcomes Study 36-Item Short-Form Health Survey), and the two groups' results were compared. RESULTS:QF and HF were significantly lower in subjects on corticosteroids than in the control patients (QF, 52.6 ± 25.6 vs 77.1 ± 33.3 %predicted, P < 0.001; HF, 63.8 ± 22.4 vs 81.8 ± 28.3 %predicted, P < 0.001, respectively). There were no significant differences in the 6MWD, ADL score and all subscales of the SF-36 between the groups. Inverse correlations were found between skeletal muscle strength and total amount of corticosteroids administered (QF, r = -0.401, P = 0.005; HF, r = -0.403, P = 0.005). On multiple regression analysis, the total amount of corticosteroids was an independent predictor of HF. CONCLUSION: Chronic cor3ticosteroid treatment contributes to muscle weakness in ILDpatients, and muscle weakness is inversely correlated to the total amount of corticosteroids administered.
Authors: Wei Ping Liu; Xiao Pei Wang; Wen Zheng; Yan Xie; Mei Feng Tu; Ning Jing Lin; Ling Yan Ping; Zhi Tao Ying; Chen Zhang; Li Juan Deng; Ning Ding; Xiao Gan Wang; Yu Qin Song; Jun Zhu Journal: Ann Hematol Date: 2017-10-31 Impact factor: 3.673
Authors: Arno C Hessels; Johannes H van der Hoeven; Jan Stephan F Sanders; Elisabeth Brouwer; Abraham Rutgers; Coen A Stegeman Journal: PLoS One Date: 2019-02-04 Impact factor: 3.240
Authors: Amritpal Dhaliwal; Jonathan I Quinlan; Kellie Overthrow; Carolyn Greig; Janet M Lord; Matthew J Armstrong; Sheldon C Cooper Journal: Nutrients Date: 2021-02-17 Impact factor: 5.717